Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials

BACKGROUND: SHR7390 is a novel, selective MEK1/2 inhibitor. Here, we report results from two phase I trials conducted to evaluate the tolerability, safety and antitumor activity of SHR7390 monotherapy for advanced solid tumors and SHR7390 plus camrelizumab for treatment-refractory advanced or metast...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Xiao-Li, Zhang, Yang, Zhao, Hong-Yun, Fang, Wen-Feng, Luo, Hui-Yan, Qiu, Miao-Zhen, He, Ming-Ming, Zou, Ben-Yan, Xie, Jie, Jin, Chun-Lei, Zhou, Xian-Feng, Wang, Feng, Wang, Feng-Hua, Li, Yu-Hong, Wang, Zhi-Qiang, Xu, Rui-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Immuno-Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847543/
https://www.ncbi.nlm.nih.gov/pubmed/36398872
http://dx.doi.org/10.1093/oncolo/oyac225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847543/
https://www.ncbi.nlm.nih.gov/pubmed/36398872
http://dx.doi.org/10.1093/oncolo/oyac225

Ejemplares similares